Real-Time Insights into Alzheimer’s Disease: A Novel Approach to Understanding Metal-Protein Interactions

Researchers at Oregon State University have developed a new technique to observe, in real-time, the chemical processes linked to Alzheimer’s disease. This breakthrough offers a more detailed understanding of how metal ions interact with proteins, potentially paving the way for more effective drug designs and treatments.

The Link Between Metals and Alzheimer’s Disease

Alzheimer’s disease, the most common form of dementia, affects millions of older adults and is currently the sixth-leading cause of death for people age 65 and older, according to the Centers for Disease Control and Prevention . A key characteristic of the disease is the aggregation of amyloid-beta proteins, which disrupts communication between brain cells. Whereas the brain requires certain metals to function properly, an imbalance in these metals can contribute to the formation of these harmful protein clumps.

Observing the Invisible: A New Methodology

Led by Marilyn Rampersad Mackiewicz, associate professor of chemistry at Oregon State University, the research team utilized a molecule measuring technique to observe how metals promote the clumping of amyloid-beta proteins. Their work, published in The Journal of Physical Chemistry C, also examined how molecules known as chelators could disrupt or reverse this clumping process.

“Too many of some metal ions, like copper, can interact with amyloid-beta proteins in ways that lead to protein aggregation, but most experiments have only shown the conclude result, not the interactions and aggregation process itself,” explained Mackiewicz . “We developed a method that lets us observe those interactions live, second by second and directly measure how different molecules interrupt or reverse them. It shifts the question from ‘does something work?’ to ‘how does it work, and when?’”

Chelators: A Closer Look

Chelators, named after the Greek word for “claw,” are molecules that bind to metal ions. The study examined two different chelators. One was found to bind to metal ions non-selectively, meaning it didn’t distinguish between metals that promote aggregation and those that don’t. However, the other chelator demonstrated a strong ability to selectively bind to copper ions, which are believed to play a significant role in Alzheimer’s disease.

Implications for Future Treatments

This real-time insight into protein aggregation and reformation is crucial for designing more effective Alzheimer’s treatments. Understanding how and when chelators alter metal-mediated aggregation is more valuable than simply determining if they work at all. Mackiewicz suggests that this approach could also explain why some existing chemical approaches haven’t performed as expected.

“Alzheimer’s affects millions of families and while clinical treatments based on this work remain years away, discoveries like this can offer genuine hope – with the correct targeting, some of the brain damage might be reversible,” Mackiewicz stated .

Next Steps and Collaborative Research

The research team, which included undergraduate students from Oregon State University and Portland State University, is now planning to test their findings in more complex biological systems, including cellular and preclinical models. Mackiewicz noted that many potential Alzheimer’s treatments fail due to an incomplete understanding of amyloid-beta protein aggregation, and their work provides a roadmap for creating more effective therapies.

Marilyn Rampersad Mackiewicz’s research focuses on engineering safe nanomaterials and understanding nanoparticle-biological interactions .